Anixa BiosciencesANIX -2.60%27 EBITDA Margin % is 0.00% as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, Anixa Biosciences ranks worse than 105932.1% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Anixa Biosciences's EBITDA for the
three
months ended in Apr. 2026 was $-2.64 Mil. Anixa Biosciences's Revenue for the
three
months ended in Apr. 2026 was $0.00 Mil. Therefore, Anixa Biosciences's EBITDA margin for the quarter that ended in Apr. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Anixa Biosciences EBITDA Margin % Related Terms
Anixa Biosciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Anixa Biosciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANIX vs PYPD, LONA, SGMO: EBITDA Margin % Comparison
For the Biotechnology subindustry, Anixa Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anixa Biosciences EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anixa Biosciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Anixa Biosciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anixa Biosciences (ANIX) has a EBITDA Margin % of 0.00% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anixa Biosciences and its competitors. According to the industry distribution chart, Anixa Biosciences ranks #999999 out of 944 companies in the Biotechnology industry.
Is Anixa Biosciences' EBITDA Margin % too high?
Anixa Biosciences' current EBITDA Margin % is 0.00%. Based on the distribution chart, Anixa Biosciences ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' EBITDA Margin % compare to PYPD and LONA?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #999999 out of 944 companies for EBITDA Margin %. This places Anixa Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current EBITDA Margin % is 0.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score
Get the complete analysis for ANIX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIX has been successfully added to your 
